Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.69 |
| ▸ | CNR2 | P34972 | 5/20 | 0.69 |
| ▸ | NAAA | Q02083 | 3/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619194 | 0.89 | CNR2 (0.67) | CNR1CNR2HTTHPGDALDH1A1 | |
| SCHEMBL1620790 | 0.88 | CNR2 (0.67) | CNR1CNR2PDE5AHTT | |
| SCHEMBL1621324 | 0.87 | CNR1 (0.64) | CNR1CNR2NAAAPDE5AHTT | |
| SCHEMBL1621363 | 0.87 | CNR2 (0.68) | CNR1CNR2HPGDALDH1A1 | |
| SCHEMBL1620397 | 0.86 | CNR1 (0.69) | CNR1CNR2HTTEPHX1ALDH1A1 | |
| SCHEMBL1619420 | 0.86 | CNR1 (0.53) | CNR1CNR2NAMPTEPHX1 | |
| SCHEMBL1620940 | 0.86 | CNR1 (0.71) | CNR1CNR2NAMPTTSHR | |
| SCHEMBL1620521 | 0.86 | CNR1 (0.67) | CNR1CNR2PDE5AHTT | |
| SCHEMBL1621357 | 0.85 | CNR2 (0.66) | CNR1CNR2PDE5AHTT | |
| SCHEMBL1620861 | 0.85 | CNR1 (0.62) | CNR1CNR2HPGDEPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | disclosed |
| EP-2203427-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | Abbott Healthcare Products B.V. (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037244-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | CNR1 1/4885CNR2 2/4885NAAA 1085/4885 |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | CNR1 1/4885CNR2 2/4885NAAA 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.